Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.
Vertero has raised $20.0M in total funding. The most recent round was Series D. The last funding was announced in October 2025.
Vertero's investors include Longwood Fund, Seventure Partners, Taiho Ventures, UTokyo Innovation Platform, Autism Impact Fund.
Vertero is headquartered in Woburn, United States.
Vertero Therapeutics is using cutting-edge research outside of the brain to treat neurodegenerative illnesses.
Vertero is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vertero — Funding & Investors." VCBacked, October 21, 2025, https://www.vcbacked.co/company/vertero. Accessed September 14, 2026.
VCBacked. (2025). Vertero — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/vertero
{{cite web |title=Vertero — Funding & Investors |url=https://www.vcbacked.co/company/vertero |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated